


Let us help you navigate the complexities of market access and deliver your evidence synthesis outputs with confidence and increased payer certainty.
At GIPAM, we are passionate about guiding our clients through the currents of pre- and post-market access challenges with robust, clinically relevant evidence generation. Critical to this journey, is a well-executed evidence synthesis strategy.
Whether you're conducting a targeted literature review (TLR) for early evidence planning or a systematic literature review (SLR) and indirect treatment comparison (ITC) for a regional or national health technology assessment (HTA), your evidence must be methodologically sound and communicate product value efectively.
What Sets Us Apart?
Expert-Led
Integrated
Automated
Our Solutions
Item 1 of 8
Related Whitepaper & Publications
Item 1 of 12